{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T10:27:52Z","timestamp":1793528872969,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016338","name":"Imperial Experimental Cancer Medicine Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014461","name":"The National Institute for Health Research Biomedical Research Centre for cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006662","name":"National Institute on Handicapped Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007568","name":"Urology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007568","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000771","name":"Prostate Cancer UK","doi-asserted-by":"publisher","award":["PG10-17"],"award-info":[{"award-number":["PG10-17"]}],"id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["MR\/R014043\/1"],"award-info":[{"award-number":["MR\/R014043\/1"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR304727"],"award-info":[{"award-number":["NIHR304727"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euo.2026.05.018","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:08:38Z","timestamp":1781640518000},"page":"1127-1137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Concomitant MRI-detected and MRI-undetected Prostate Cancer with Implications for Biopsy Strategies and Focal Therapy Planning: An Analysis of the PROMIS and PICTURE Trials"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7246-3651","authenticated-orcid":false,"given":"Alexander","family":"Light","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Gopalakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Mayor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Emberton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashim U.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taimur T.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.05.018_b0005","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2026.05.018_b0010","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/bjc.2017.57","article-title":"The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy","volume":"116","author":"Simmons","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2026.05.018_b0015","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(18)30569-2","article-title":"Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study","volume":"20","author":"Rouvi\u00e8re","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.05.018_b0020","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2022.01.008","article-title":"Targeted prostate biopsy: umbra, penumbra, and value of perilesional sampling","volume":"82","author":"Brisbane","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.05.018_b0025","doi-asserted-by":"crossref","first-page":"7544","DOI":"10.1007\/s00330-022-08822-3","article-title":"Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy","volume":"32","author":"Deniffel","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1016\/j.euo.2026.05.018_b0030","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bju.16579","article-title":"Clinical value of contralateral biopsies in men with unilateral MRI foci undergoing targeted biopsy","volume":"135","author":"Boesen","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.05.018_b0035","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.euo.2024.10.006","article-title":"Regional versus systematic biopsy in addition to targeted biopsy: results from a systematic review and meta-analysis","volume":"8","author":"Sanguedolce","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.05.018_b0040","doi-asserted-by":"crossref","unstructured":"Baboudjian M, Uleri A, Anract J, et al. Targeted, perilesional, and distant biopsies in prostate cancer. Eur Urol Oncol. In press. https:\/\/doi.org\/10.1016\/j.euo.2026.02.006.","DOI":"10.1016\/j.euo.2026.02.006"},{"key":"10.1016\/j.euo.2026.05.018_b0045","unstructured":"Prostate cancer. European Association of Urology. Accessed March 1, 2025. https:\/\/uroweb.org\/guidelines\/prostate-cancer."},{"key":"10.1016\/j.euo.2026.05.018_b0050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.eururo.2021.08.005","article-title":"An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years?","volume":"81","author":"Hopstaken","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.05.018_b0055","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/bju.15883","article-title":"Guidelines of guidelines: focal therapy for prostate cancer, is it time for consensus?","volume":"131","author":"Ong","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.05.018_b0060","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/bju.16669","article-title":"Refining partial gland ablation for localised prostate cancer: the Falcon project","volume":"135","author":"Rodriguez-Sanchez","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.05.018_b0065","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.juro.2015.02.080","article-title":"Image guided focal therapy for magnetic resonance imaging visible prostate cancer: defining a 3-dimensional treatment margin based on magnetic resonance imaging histology co-registration analysis","volume":"194","author":"Le Nobin","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.05.018_b0070","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/bju.15355","article-title":"Defining prostate cancer size and treatment margin for focal therapy: does intralesional heterogeneity impact the performance of multiparametric MRI?","volume":"128","author":"Aslim","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.05.018_b0075","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/JU.0000000000001389","article-title":"Predicting pathological tumor size in prostate cancer based on multiparametric prostate magnetic resonance imaging and preoperative findings","volume":"205","author":"Pooli","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.05.018_b0080","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.euros.2023.05.018","article-title":"Prediction and mapping of intraprostatic tumor extent with artificial intelligence","volume":"54","author":"Priester","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2026.05.018_b0085","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.eururo.2020.04.029","article-title":"What type of prostate cancer is systematically overlooked by multiparametric magnetic resonance imaging? An analysis from the PROMIS cohort","volume":"78","author":"Norris","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.05.018_b0090","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.euo.2019.06.005","article-title":"Is there still a need for repeated systematic biopsies in patients with previous negative biopsies in the era of magnetic resonance imaging-targeted biopsies of the prostate?","volume":"3","author":"Exterkate","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.05.018_b0095","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.euros.2021.06.003","article-title":"Which prostate cancers are undetected by multiparametric magnetic resonance imaging in men with previous prostate biopsy? An analysis from the PICTURE study","volume":"30","author":"Norris","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2026.05.018_b0100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/bju.13090","article-title":"Combination of multiparametric MRI and transperineal template-guided mapping biopsy of the prostate to identify candidates for hemi-ablative focal therapy","volume":"117","author":"Tran","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.05.018_b0105","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","volume":"75","author":"van der Leest","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.05.018_b0110","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1910038","article-title":"MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis","volume":"382","author":"Ahdoot","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.05.018_b0115","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20200298","article-title":"Comparison of Likert and PI-RADS version 2 MRI scoring systems for the detection of clinically significant prostate cancer","volume":"93","author":"Zawaideh","year":"2020","journal-title":"Br J Radiol"},{"key":"10.1016\/j.euo.2026.05.018_b0120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/bju.14916","article-title":"Likert vs PI-RADS v2: A comparison of two radiological scoring systems for detection of clinically significant prostate cancer","volume":"125","author":"Khoo","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.05.018_b0125","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/bju.16155","article-title":"Prostagram magnetic resonance imaging in a screening population: prostate Imaging-Reporting and Data System or Likert?","volume":"133","author":"Mayor","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.05.018_b0130","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1464-410X.2005.05801.x","article-title":"Clinical staging of prostate cancer: A computer-simulated study of transperineal prostate biopsy","volume":"96","author":"Crawford","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.05.018_b0135","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/bju.13306","article-title":"Transperineal template prostate-mapping biopsies: an evaluation of different protocols in the detection of clinically significant prostate cancer","volume":"118","author":"Valerio","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.05.018_b0140","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.euros.2024.03.006","article-title":"The impact of omitting contralateral systematic biopsy on the surgical planning of patients with a unilateral suspicious lesion on magnetic resonance imaging undergoing robot-assisted radical prostatectomy for prostate cancer","volume":"63","author":"van den Kroonenberg","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2026.05.018_b0145","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.juro.2018.06.033","article-title":"Patient reported outcome measures for transperineal template prostate mapping biopsies in the PICTURE study","volume":"200","author":"Miah","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.05.018_b0150","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.urology.2013.02.019","article-title":"Morbidity after transperineal prostate biopsy in 3000 patients undergoing 12 vs 18 vs more than 24 needle cores","volume":"81","author":"Pepe","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.euo.2026.05.018_b0155","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMcibr0905562","article-title":"The index lesion and the origin of prostate cancer","volume":"361","author":"Ahmed","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.05.018_b0160","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.euo.2021.02.008","article-title":"A systematic review of prostate cancer heterogeneity: understanding the clonal ancestry of multifocal disease","volume":"4","author":"Erickson","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.05.018_b0165","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.eururo.2015.01.030","article-title":"Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study","volume":"68","author":"Ahmed","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.05.018_b0170","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.juro.2014.11.015","article-title":"Identifying the index lesion with template prostate mapping biopsies","volume":"193","author":"Valerio","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.05.018_b0175","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.eururo.2025.03.019","article-title":"Magnetic resonance imaging-led risk-adapted active surveillance for prostate cancer: updated results from a large cohort study","volume":"88","author":"Englman","year":"2025","journal-title":"Eur Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T09:33:08Z","timestamp":1793525588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126001586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2588931126001586"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.05.018","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concomitant MRI-detected and MRI-undetected Prostate Cancer with Implications for Biopsy Strategies and Focal Therapy Planning: An Analysis of the PROMIS and PICTURE Trials","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}